Forty Seven *

Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage therapeutics company it exposes no public developer API surface.

Forty Seven * is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immuno-Oncology, and Oncology.

🌐 Visit website 📡 Source on GitHub

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Life Sciences Biotechnology Immuno-Oncology Oncology Pharmaceuticals Cancer Therapeutics

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 3.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/forty-seven: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: forty-seven
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven.png
name: Forty Seven *
description: Forty Seven, Inc. was an immuno-oncology biotechnology company founded in 2015 to commercialize CD47 immune-evasion
  research licensed from Stanford University (Irv Weissman and colleagues). Its lead program was magrolimab, a monoclonal
  antibody targeting CD47 — the "do not eat me" signal tumor cells use to evade macrophage-mediated killing — studied in myelodysplastic
  syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). Backed by GV, the company was acquired
  by Gilead Sciences in 2020 for roughly $4.9 billion; the fortyseveninc.com domain now redirects to gilead.com. As a clinical-stage
  therapeutics company it exposes no public developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Immuno-Oncology
- Oncology
- Pharmaceuticals
- Cancer
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/forty-seven-domain-security.yml
- type: Website
  url: http://fortyseveninc.com
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence

Forty Seven *

Kin Score

Security Posture 1

Forty Seven Domain Security

Resources

Access & Security 1

Company 1

Source (apis.yml)